Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Sight Sciences, Inc. Common Stock

SGHT

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Last trade $10.55
Day change -$0.04 (-0.38%)
Day range $10.32 – $10.68
Volume 164,156
Market cap $589M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$588.58M
Price / earnings
—
Price / book
11.98×
Price / sales
6.66×
EV / sales
6.25×
EV / EBITDA
-21.5×

Profitability

Earnings per share
-$0.51
Return on assets
-27.06%
Return on equity
-57.79%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.83×
Current ratio
5.04×
Quick ratio
4.72×
Cash ratio
3.84×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.93M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SGHT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$24.92M$23.39M$19.7M$20.39M$19.91M$19.56M$17.51M$19.07M
Cost of revenue$3.5M$2.01M$2.72M$2.6M$2.71M$2.98M$2.41M$2.51M
Gross profit$21.42M$21.37M$16.98M$17.79M$17.2M$16.59M$15.09M$16.56M
Selling, general and administrative$24.84M$22.75M$26.85M$19.02M$21.75M$23.87M$24.52M$24.2M
Research and development$2.71M$2.51M$2.55M$2.44M$3.35M$4.39M$4.43M$4.29M
Total operating expenses$27.55M$25.26M$29.39M$21.46M$25.1M$28.25M$28.95M$28.49M
Operating income-$6.13M-$3.89M-$12.41M-$3.67M-$7.91M-$11.67M-$13.86M-$11.93M
Interest expense-$1.31M-$1.29M-$1.27M-$1.29M-$1.31M-$1.28M-$1.26M-$1.16M
Income before taxes-$6.8M-$4.42M-$12.97M-$4.15M-$8.25M-$11.9M-$14.11M-$11.81M
Income taxes$11K$28K$11K$8K-$79K$40K$41K$38K
Net income-$6.81M-$4.45M-$12.98M-$4.16M-$8.17M-$11.94M-$14.15M-$11.85M
Net income attributable to common shareholders-$6.81M-$4.45M-$12.98M-$4.16M-$8.17M-$11.94M-$14.15M-$11.85M
EBITDA-$6.02M-$3.79M-$12.31M-$3.56M-$7.8M-$11.54M-$13.71M-$11.75M
Basic earnings per share-$0.12-$0.08-$0.24-$0.08-$0.16-$0.23-$0.28-$0.23
Diluted earnings per share-$0.12-$0.08-$0.24-$0.08-$0.16-$0.23-$0.28-$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Sight Sciences, Inc. (SGHT) is a Great Momentum Stock: Should You Buy?

Sight Sciences (SGHT) is highlighted as a momentum stock with a Zacks Rank #2 (Buy) rating and Momentum Style Score of B. The stock has outperformed its industry significantly, gaining 8.15% weekly, 32.36% monthly, and 41.45% annually. Recent earnings estimate revisions have been positive, with upward revisions for both current and next fiscal year estimates, suggesting continued momentum potential.

Zacks Investment Research

Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Sight Sciences reported Q3 2026 revenue of $24.92 million, up 25.2% year-over-year and beating consensus estimates by 6.46%. The company posted an EPS of -$0.12, matching expectations. Interventional Dry Eye revenue surged 1962.2% to $3.88 million, while Interventional Glaucoma revenue grew 6.7% to $21.05 million. Both segments exceeded analyst estimates. The stock has a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) reported a quarterly loss of $0.12 per share matching consensus estimates, with revenues of $24.92 million exceeding expectations by 6.46%. The company has outperformed the market by 18.8% year-to-date but received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

A cost-utility analysis revealed that TearCare® System offers cost savings and better health utility compared to cyclosporine 0.05% for treating meibomian gland disease-associated dry eye disease, with $903 annual per-patient savings.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.